Flash Finance

Aurobindo Pharma LimitedAUROPHARMACorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,666.90
MCap ₹95,910 Cr · P/E 37.0
Aurobindo Pharma Limited — Stock analysis & AI research Aurobindo Pharma Limited — Multibagger AI analysis Aurobindo Pharma Limited — Seasonality — best & worst months Aurobindo Pharma Limited — Technical indicators & charts Aurobindo Pharma Limited — Technical setup — score, trend, support & resistance Aurobindo Pharma Limited — Rectangle / Trading Range pattern forming Aurobindo Pharma Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Mid Cap Stocks List 📈 Stocks Near 52-Week High📈 Bollinger Squeeze Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,800 Cr
Sales · Jun 2026
-1.7% YoY
₹882 Cr
Operating Profit · Jun 2026
+10.8% YoY
31.5%
OPM % · Jun 2026
+12.5% YoY
₹737 Cr
Net Profit · Jun 2026
+31.9% YoY
₹12.75
EPS · Jun 2026
+32.4% YoY

📝 Aurobindo Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Aurobindo Pharma Limited reported revenue of ₹2,800 crore for the quarter ended June 2026 (Q1 FY27), down 1.7% from ₹2,848 crore in the same quarter last year, and up 0.4% sequentially over the March 2026 quarter.

Net profit rose 31.9% year-on-year to ₹737 crore, from ₹559 crore. Earnings per share (EPS) came in at ₹12.75.

Operating profit stood at ₹882 crore — an operating margin (OPM) of 31.5%, compared with 28.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Aurobindo Pharma Limited posted revenue of ₹11,172 crore, a growth of 2.2% over FY25, with a net profit of ₹2,415 crore (up 38.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹11,124 crore with a net profit of ₹2,593 crore.

Valuation snapshot

At the current price of ₹1,666.90, AUROPHARMA has a market capitalisation of ₹95,910 crore and a trailing P/E of about 37.0.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 8th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.88%, foreign institutional investors (FIIs) 17.41%, domestic institutional investors (DIIs) 24.42%, public shareholders 6.29% of Aurobindo Pharma Limited.

Promoter holding rose from 51.82% to 51.88% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹95,910 Cr
Current Price ?
₹1,666.9
P/E ?
36.99above ind
Industry P/E ?
35.00
P/B ?
4.22
P/S ?
8.62
P/FCF ?
38.75
Enterprise Value ?
₹100,195 Cr
EV/EBITDA ?
31.53
PEG ?
1.42
Earnings Yield ?
2.9%
Dividend Yield ?
0.23%
Profitability & Returns
Sales (TTM) ?
₹11,124 Cr
OPM ?
28.6%
Profit after tax (TTM) ?
₹2,593 Cr
EPS (TTM) ?
₹45.06
ROCE ?
13.0%
ROE ?
11.4%
ROA ?
8.9%
Growth
Sales — latest qtr ?
₹2,800 Cr
PAT — latest qtr ?
₹737 Cr
YoY qtr sales growth ?
-1.7%
YoY qtr profit growth ?
31.9%
Sales growth (3y) ?
10%
Sales growth (5y) ?
-7%
Profit growth (3y) ?
26%
Profit growth (5y) ?
-5%
Financial Health
Debt ?
₹4,285 Cr
Debt to Equity ?
0.19
Interest Coverage ?
13.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.88%
Change in promoter holding ?
0.06%
Pledged percentage ?
N/A
Market
Return 3 months ?
8.7%
Return 6 months ?
20.3%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 3,4323,5472,3912,6692,6922,8942,4602,8252,9172,7322,8482,7902,7472,7872,800 -1.7% +0.4%
Operating Profit 473692422545482775499721713597796725789781882 +10.8% +13.0%
Other Income 792889567331123651235411484160130214242 +188.8% +13.0%
Interest 394932376153515266616057484747 -21.6% +0.1%
Depreciation 10811560666465676868947071727269 -1.5% -4.2%
Profit Before Tax 4048164265106877804467246335567507557828761,008 +34.4% +15.1%
Net Profit 299645336380624579329538472408559581582692737 +31.9% +6.5%
EPS 5.1011.005.736.4810.659.885.629.218.137.039.6310.0110.0211.9212.75 +32.4% +7.0%
OPM % 13.8% 19.5% 17.7% 20.4% 17.9% 26.8% 20.3% 25.5% 24.5% 21.8% 28.0% 26.0% 28.7% 28.0% 31.5% +12.5% +12.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹10,933 Cr ₹11,172 Cr ₹11,124 Cr +2.2%
Operating Profit ₹2,529 Cr ₹3,092 Cr ₹3,177 Cr +22.2%
OPM % 23.14% 27.67% 28.56% +19.6%
NPM % 15.98% 21.61% 23.31% +35.2%
Other Income ₹356 Cr ₹587 Cr ₹746 Cr +64.9%
Depreciation ₹297 Cr ₹285 Cr ₹284 Cr -4.0%
Interest ₹230 Cr ₹213 Cr ₹200 Cr -7.5%
EBIT ₹2,232 Cr ₹2,806 Cr ₹2,893 Cr +25.7%
PBT ₹2,358 Cr ₹3,163 Cr ₹3,421 Cr +34.1%
Tax ₹612 Cr ₹565 Cr ₹645 Cr -7.7%
Net Profit ₹1,747 Cr ₹2,415 Cr ₹2,593 Cr +38.2%
EPS ₹29.99 ₹41.58 ₹44.70 +38.6%
Material Cost ₹5,675 Cr ₹4,043 Cr ₹3,978 Cr -28.8%
Employee Cost ₹1,063 Cr ₹868 Cr ₹881 Cr -18.3%
Extraordinary Items — ₹17 Cr ₹17 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 59595858 +0.0%
Reserves 17,97519,66420,47622,660 +10.7%
Borrowings 4,2032,8614,6474,285 -7.8%
Other Liabilities 2,8222,5702,3322,276 -2.4%
Total Liabilities 25,05925,15427,51329,279 +6.4%
Fixed Assets 3,6882,4192,3372,544 +8.9%
CWIP 23913388229 +160.2%
Investments 8,10513,39315,21017,562 +15.5%
Other Assets 13,0279,2099,8798,945 -9.5%
Total Assets 25,05925,15427,51329,279 +6.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,8161,7151,6462,933 +78.2%
Cash from Investing Activity -3,230-152-2,050-2,025 +1.2%
Cash from Financing Activity 1,719-1,837616-1,072 -274.0%
Net Cash Flow 306-274212-164 -177.4%
Free Cash Flow 1,4811,2931,4542,475 +70.2%
CFO/OP 141%104%91%120% +31.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 197129140138 -1.4%
Inventory Days 335148154161 +4.5%
Days Payable 179112116125 +7.8%
Cash Conversion Cycle 353166177174 -1.7%
Working Capital Days 126653251 +59.4%
ROCE % 8%12%11%13% +18.2%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 51.82%51.82%51.82%51.82%51.88% +0.1%
FIIs 14.38%14.21%13.95%15.24%17.41% +14.2%
DIIs 26.93%27.60%27.66%25.82%24.42% -5.4%
Government 0.00%0.00%0.03%0.05%— —
Public 6.88%6.37%6.55%7.08%6.29% -11.2%
No. of Shareholders 2,72,2082,47,6622,36,8592,41,2982,33,737 -3.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Aurobindo Pharma Limited's revenue in Q1 FY27?
Aurobindo Pharma Limited reported revenue of ₹2,800 crore for the quarter ended June 2026 (Q1 FY27), down 1.7% from ₹2,848 crore in the same quarter last year, and up 0.4% sequentially over the March 2026 quarter.
What was Aurobindo Pharma Limited's net profit in Q1 FY27?
Net profit rose 31.9% year-on-year to ₹737 crore, from ₹559 crore. Earnings per share (EPS) came in at ₹12.75.
What is AUROPHARMA's market capitalisation and P/E ratio?
At the current price of ₹1,666.90, AUROPHARMA has a market capitalisation of ₹95,910 crore and a trailing P/E of about 37.0.
Who owns Aurobindo Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.88%, foreign institutional investors (FIIs) 17.41%, domestic institutional investors (DIIs) 24.42%, public shareholders 6.29% of Aurobindo Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI